The Club's 10 things to watch in the stock market Friday

S&P futures are flat amid renewed regional bank credit quality concerns, with Zions Bancorp and Western Alliance alleging fraud in bad loans, though analysts suggest the market reaction to these specific issues may be overdone. In corporate developments, Jefferies received an upgrade, while DuPont was highlighted as a short-term buy ahead of its Qnity electronics spin-off. Advanced Micro Devices (AMD) saw its price target raised by Bank of America on AI hardware optimism, and Oracle and Eaton also received price target hikes following strong outlooks. Conversely, Eli Lilly shares declined on renewed GLP-1 drug pricing concerns, contrasting with American Express's strong quarterly performance and positive outlook for its premium card segment, which showed no signs of consumer credit deterioration.

Analysis

Regional bank credit quality concerns, stemming from Zions Bancorp and Western Alliance's alleged fraud in bad loans, contributed to S&P futures flatness following yesterday's sell-off. However, Baird upgraded Zions to buy, arguing the $1 billion market cap loss on a $50 million charge-off was "overdone," suggesting the issue is unique rather than systemic. Similarly, Jefferies was upgraded to buy by Oppenheimer, as its First Brands exposure was deemed "very limited" after a 27% share decline.

Positive analyst sentiment emerged for several technology and industrial companies. Bank of America raised Advanced Micro Devices' price target to $300, implying 30% upside, citing optimism for its Helios rack-scale AI hardware platform. Oracle received multiple price target hikes after outlining updated long-term financial targets, though analysts questioned its data center build capacity. Eaton also saw its price target increased to $425 by Mizuho, positioning it as a beneficiary of energy-intensive AI data centers.

DuPont was highlighted as a short-term buy idea by Deutsche Bank, with a sum-of-the-parts valuation suggesting a 38% discount ahead of its Qnity electronics spin-off. Conversely, Eli Lilly shares declined 4% due to renewed GLP-1 drug pricing concerns, despite President Trump's comments specifically targeting a rival. American Express, however, delivered a strong quarterly beat and raised full-year revenue guidance, showing no signs of consumer credit deterioration in its premium card segment.

Key Decisions for Investors

• Investors should closely monitor regional bank credit quality, distinguishing between systemic risks and isolated fraud allegations, potentially identifying undervalued opportunities in names like Zions and Jefferies.
• Evaluate AI-driven growth opportunities in companies like AMD, Oracle, and Eaton, while scrutinizing execution risks such as Oracle's data center expansion capabilities.
• Assess the impact of potential pricing pressure in the GLP-1 drug market on pharmaceutical holdings, and observe the resilience of premium consumer spending as indicated by American Express's strong performance amidst broader credit concerns.